| |
Primary mission
|
Secondary mission
|
|---|
|
Total (n = 425)
|
225
|
200
|
|
Gender
| | |
|
Male
|
142 (63.1%)
|
115 (57.7%)
|
|
Age
| | |
|
median (IQR)
|
6.4 (2.4–12.7)
|
5 (1.7–10.5)
|
|
NACA
| | |
|
III
|
1 (0.4%)
|
1 (0.5%)
|
|
IV
|
31 (13.8%)
|
75 (37.5%)
|
|
V
|
116 (51.6%)
|
116 (58%)
|
|
VI
|
43 (19.1%)
|
8 (4%)
|
|
VII
|
34 (15.1%)
|
0
|
|
GCS
| | |
|
< 9
|
206 (91.5%)
|
184 (92%)
|
|
> = 9
|
19 (8.5%)
|
16 (8%)
|
|
Trauma
|
151 (67.1%)
|
69 (34.5%)
|
|
Craniofacial injury
|
117 (77.5%)
|
55 (79.7%)
|
|
Other
|
34 (22.5%)
|
14 (20.3%)
|
|
Non-trauma
|
74 (32.9%)
|
131 (65.5%)
|
|
Neurological
|
20 (27%)
|
40 (30.5%)
|
|
Respiratory
|
37 (50%)
|
12 (9.2%)
|
|
Circulatory
|
13 (17.6%)
|
53 (40.5%)
|
|
Other
|
4 (5.4%)
|
26 (19.8%)
|
|
Airway (final)
| | |
|
NIV
|
4 (1.8%)
|
5 (2.5%)
|
|
Tracheotomy (pre-existing)
|
3 (1.3%)
|
5 (2.5%)
|
|
Orotracheal int.
|
212 (94.2%)
|
172 (86%)
|
|
Nasotracheal int.
|
0
|
18 (9%)
|
|
Laryngeal mask
|
2 (0.9%)
|
0
|
|
Laryngeal tube
|
3 (1.3%)
|
0
|
|
CICV
|
1 (0.4%)
|
n/a
|
|
Neuromuscular blocking agents used (NACA III-V)
|
129/148 (87.2%)
|
n/a
|
|
Rocuronium
|
34 (26.4%)
|
|
Suxamethonium
|
95 (73.6%)
|
|
Neuromuscular blocking agents used (NACA VI-VII)
|
11/77 (13.3%)
|
n/a
|
|
Rocuronium
|
6 (54.5%)
|
|
Suxamethonium
|
5 (45.5%)
|
- Summary of primary and secondary mission characteristics. Percentages are in reference to the main group (primary/secondary) or the subgroup respectively. IQR interquartile range. NACA national advisory committee for aeronautics. GCS glasgow coma scale. NIV non-invasive ventilation. CICV cannot intubate, cannot ventilate
